Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

PURPOSE: To evaluate drug–drug interactions between the human epidermal growth factor receptor 2 (HER2)–targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole. PATIENTS AND METHODS: Patients with H...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shunji, Karayama, Masato, Takahashi, Masato, Watanabe, Junichiro, Minami, Hironobu, Yamamoto, Noboru, Kinoshita, Ichiro, Lin, Chia-Chi, Im, Young-Hyuck, Achiwa, Issei, Kamiyama, Emi, Okuda, Yasuyuki, Lee, Caleb, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401457/
https://www.ncbi.nlm.nih.gov/pubmed/34426442
http://dx.doi.org/10.1158/1078-0432.CCR-21-1560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401457/
https://www.ncbi.nlm.nih.gov/pubmed/34426442
http://dx.doi.org/10.1158/1078-0432.CCR-21-1560

Ejemplares similares